There is at least one other who would be able to produce mesenchymal cells in quantity and are in later stage trials for Covid-19, that would be Takeda. Either via Lonza or via their own manufacturing facility in Ireland if it is finished.
On 12 Feb 2015 Tigenix entered and agreement with Lonza to manufacture Cx601 product for TiGenix’s Phase 3 trial in the US at Lonza’s Walkersville, Maryland (US) facility.
https://www.lonza.com/news/150212-tigenix-e
That product, Cx601, went on to become Alofisel which is covered by a licensing agreement with Mesoblast.
That may also be a Lonza site that Mesoblast could use for US manufacturing if needed. Just conjecture on my part, I'd be quite certain all that kind of detail or scenarios were covered weeks or months ago between Mesoblast and Lonza.
Fiercepharma report Takeda is spending €25 million ($30.5 million) to build a standalone modular cell therapy facility in Ireland, originally reported due for completion in 2021.
It does not appear to have been finished yet, only because I can find no news updates, it would be the P3 facility at Grange Castle for commercial scale cell therapy production. Probably not too far away if not ready just yet. Probably a bit more impetus with their trial in Spain.
Cell Therapy News/Articles, page-1350
-
- There are more pages in this discussion • 16,494 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |